Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells

Effects of post-transplant cyclophosphamide on immune reconstitution after haploidentical and HLA-matched transplant.

Blood advances·2026

Flow MRD pre-blinatumomab consolidation, despite subsequent clearance, is associated with inferior survival in Ph+ B-ALL.

Blood advances·2026

Germline DDX41 defines a distinct subgroup in MDS undergoing transplantation with reduced relapse and improved survival.

Blood·2026

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Blood advances·2026

Outcomes of adolescents and young adults with AML treated on pediatric vs adult protocols.

Blood advances·2026

Development of a Fully Non-Viral 1XX-enhanced BCMA CAR-T Cell Therapy for Multiple Myeloma.

bioRxiv : the preprint server for biology·2026

Patients' preferences for accepting risks and uncertainty in AML treatments within European public health care systems: a cross-sectional study in Finland, Italy, and Germany.

Leukemia & lymphoma·2026

Time burden and treatment patterns of patients with newly diagnosed acute myeloid leukemia receiving parenteral hypomethylating agents in combination with venetoclax.

Leukemia & lymphoma·2026

Care pathway of patients with second-line large B-cell lymphoma treated with CAR T-cell therapies in France.

Leukemia & lymphoma·2026

Zanubrutinib with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory non-germinal center B-cell lymphoma.

Leukemia & lymphoma·2026

Secondary minimally differentiated acute leukemia with plasmacytoid dendritic cell differentiation (pDC-AML) following chemoradiotherapy for Ewing sarcoma in a child: biallelic EZH2 inactivation.

Leukemia & lymphoma·2026

PTCy, sirolimus, MMF and RGI-2001 to explore regulatory T-cell expansion following haploidentical peripheral blood stem cell transplantation: a pilot study.

Leukemia & lymphoma·2026

Cardiac adverse event signals of Bruton's tyrosine kinase inhibitors as primary suspect and in co-reported regimens: a large-scale FAERS pharmacovigilance study.

Frontiers in pharmacology·2026

Can we better evaluate responses in higher-risk myelodysplastic syndromes?

Haematologica·2026

Dynamics and clinical significance of coagulation abnormalities following CAR T-cell therapy.

Haematologica·2026

NEDD4 Promotes Hepatocellular Carcinoma Progression Through Ubiquitin-Dependent Degradation of EPHB6.

Cancer science·2026

WNT5A-Associated Osteogenic Enhancement Contributes to the Protective Effects of OPG-Fc in Glucocorticoid-Associated Femoral Head Osteonecrosis.

Biomolecules & therapeutics·2026

Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells

Related Experiment Videos

Related Concept Videos

Effects of post-transplant cyclophosphamide on immune reconstitution after haploidentical and HLA-matched transplant.

Flow MRD pre-blinatumomab consolidation, despite subsequent clearance, is associated with inferior survival in Ph+ B-ALL.

Germline DDX41 defines a distinct subgroup in MDS undergoing transplantation with reduced relapse and improved survival.

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Outcomes of adolescents and young adults with AML treated on pediatric vs adult protocols.

Development of a Fully Non-Viral 1XX-enhanced BCMA CAR-T Cell Therapy for Multiple Myeloma.

Patients' preferences for accepting risks and uncertainty in AML treatments within European public health care systems: a cross-sectional study in Finland, Italy, and Germany.

Time burden and treatment patterns of patients with newly diagnosed acute myeloid leukemia receiving parenteral hypomethylating agents in combination with venetoclax.

Care pathway of patients with second-line large B-cell lymphoma treated with CAR T-cell therapies in France.

Zanubrutinib with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory non-germinal center B-cell lymphoma.

Secondary minimally differentiated acute leukemia with plasmacytoid dendritic cell differentiation (pDC-AML) following chemoradiotherapy for Ewing sarcoma in a child: biallelic EZH2 inactivation.

PTCy, sirolimus, MMF and RGI-2001 to explore regulatory T-cell expansion following haploidentical peripheral blood stem cell transplantation: a pilot study.

Cardiac adverse event signals of Bruton's tyrosine kinase inhibitors as primary suspect and in co-reported regimens: a large-scale FAERS pharmacovigilance study.

Can we better evaluate responses in higher-risk myelodysplastic syndromes?

Dynamics and clinical significance of coagulation abnormalities following CAR T-cell therapy.

NEDD4 Promotes Hepatocellular Carcinoma Progression Through Ubiquitin-Dependent Degradation of EPHB6.

WNT5A-Associated Osteogenic Enhancement Contributes to the Protective Effects of OPG-Fc in Glucocorticoid-Associated Femoral Head Osteonecrosis.

Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells

Related Experiment Videos

Related Concept Videos

Related Articles